Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02326935
Other study ID # CRYO-MS-ADSC-006
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date November 2014
Est. completion date May 18, 2018

Study information

Verified date May 2018
Source American CryoStem Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The intent of this clinical study is to answer the questions: 1) is the proposed treatment safe and 2) is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes.


Description:

This will be an open-label, non-randomized multi-center patient sponsored study of ADSC implantation using an IV delivery system. The study will provide therapies to up to 100 qualified patients who match the inclusion/exclusion criteria, agree to the follow up program and who have provided a signed consent for each procedure.

The treatment is a combination of (a) general detoxification, (b) lymphatic massage/drainage, (c) therapeutic massage, reflexology and acupuncture and (d) cellular infusion therapy in which cells will be deployed via IV injection over two treatments of 60 minutes each during the five (5) day treatment period.

Follow-up data based upon MSIS-29, a modified SF-36 and standard complication questionnaire will be collected at 3, 6 and then annually post treatment by the patients' local physician and reported back to the sponsor where it will be logged into a HIPPA-compliant outcomes database.

Additional safety data, based upon a standard complication questionnaire will be collected via survey of patient at intervals of 3 and 6 months and then annually for a minimum of five (5) years.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date May 18, 2018
Est. primary completion date May 18, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Confirmed Diagnosis of MS

- Aged 18 - 65 years.

- Duration of disease: >5 years

- Signed, written informed consent willing and able to comply with study visits according to protocol for the full study period

- Physically, mentally and legally capable of international travel for treatment

Exclusion Criteria:

- Patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results

- Patient with any active or chronic infection

- No life-threatening organ dysfunction.

- Pregnancy or risk of pregnancy.

- Severe physical limitations or disabilities

- Patients who are seropositive for HIV1, HIV2, Hepatitis B Surface Antigen, and Hepatitis C

- Patients unable to give written informed consent in accordance with research ethics board guidelines

- Treatment with any immunosuppressive therapy within the 3 months prior to randomization

- Current treatment with an investigational therapy

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Autologous adipose derived mesenchymal cells
Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.

Locations

Country Name City State
Cayman Islands The Da Vinci Center George Town

Sponsors (1)

Lead Sponsor Collaborator
American CryoStem Corporation

Country where clinical trial is conducted

Cayman Islands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Standard Complication Questionnaire incidence and nature of adverse events, serious adverse events, or any unanticipated adverse events. The nature, incidence, and rate of adverse events will be assessed 3 months
Primary MS Impact Scale - MSIS-29 Multiple Sclerosis Impact Scale (MSIS-29) 3 months
Primary Modified SF-36 Cell-Based Therapy Follow Up Modified SF-36 for Cell-Based Therapy Follow Up 3 months
Primary Physical Evaluation Vital signs of sitting blood pressure, temperature and heart rate 3 Months
Secondary MS Impact Scale - MSIS-29 Multiple Sclerosis Impact Scale (MSIS-29) 6 months
Secondary MS Impact Scale - MSIS-29 Multiple Sclerosis Impact Scale (MSIS-29) 1 year
Secondary Modified SF-36 Cell-Based Therapy Follow Up Modified SF-36 for Cell-Based Therapy Follow Up 6 months
Secondary Standard Complication Questionnaire incidence and nature of adverse events, serious adverse events, or any unanticipated adverse events. The nature, incidence, and rate of adverse events will be assessed 6 months
Secondary Standard Complication Questionnaire incidence and nature of adverse events, serious adverse events, or any unanticipated adverse events. The nature, incidence, and rate of adverse events will be assessed 1 year
Secondary Standard Complication Questionnaire incidence and nature of adverse events, serious adverse events, or any unanticipated adverse events. The nature, incidence, and rate of adverse events will be assessed 2 years
Secondary Standard Complication Questionnaire incidence and nature of adverse events, serious adverse events, or any unanticipated adverse events. The nature, incidence, and rate of adverse events will be assessed 3 years
Secondary Standard Complication Questionnaire incidence and nature of adverse events, serious adverse events, or any unanticipated adverse events. The nature, incidence, and rate of adverse events will be assessed 4 years
Secondary Standard Complication Questionnaire incidence and nature of adverse events, serious adverse events, or any unanticipated adverse events. The nature, incidence, and rate of adverse events will be assessed 5 years
Secondary Physical Evaluation incidence and nature of adverse events, serious adverse events, or any unanticipated adverse events. The nature, incidence, and rate of adverse events will be assessed 6 months
Secondary Physical Evaluation incidence and nature of adverse events, serious adverse events, or any unanticipated adverse events. The nature, incidence, and rate of adverse events will be assessed 1 Year
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4